Bavdegalutamide, a proteolysis-targeting chimera (PROTAC) degrader of the androgen receptor (AR), shows promise in prostate cancer treatment [37], while TAM-IN-2, a TAM receptor inhibitor, effectively blocks Gas6-induced AXL activation and suppresses lung cancer progression. This evidence concerns the gene GAS6 and lung carcinoma.